Late-Stage NAFLD/NASH Programs
The global NASH market is expected to hit an average of $13B annually by 2030. As of June 2020, the NASH pipeline of first wave drugs holds 54 clinical candidates in development by 47 companies evaluating 29 different mechanisms of action. Over the last two decades, the NASH pipeline has seen many late-stage programs fail to show clinical efficacy, despite targeting a broad range of mechanism of actions.
In November 2020, Back Bay Life Science Advisors will publish a detailed analysis of NASH development, The NASH Dash: Pipeline & Market Assessment by Mavra Nasir, PhD, Crystal Hsu, and Peter Bak, PhD, Back Bay Life Science Advisors.
